Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient

PURPOSE: Treatment outcomes and direct medical costs were examined, from a US health payer perspective, of monotherapy with sarilumab 200 mg subcutaneous (SC) every 2 weeks (Q2W) vs adalimumab 40 mg SC Q2W/QW in adult patients with moderately to severely active rheumatoid arthritis who are intoleran...

Descripción completa

Detalles Bibliográficos
Autores principales: Fournier, Marie, Chen, Chieh-I, Kuznik, Andreas, Proudfoot, Clare, Mallya, Usha G, Michaud, Kaleb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368117/
https://www.ncbi.nlm.nih.gov/pubmed/30787625
http://dx.doi.org/10.2147/CEOR.S183076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368117/
https://www.ncbi.nlm.nih.gov/pubmed/30787625
http://dx.doi.org/10.2147/CEOR.S183076

Ejemplares similares